Vaccine Injected Directly Into Cancer Appears Promising for Head and Neck Cancer
3/31/2005 Toronto, Ontario, Canada cancerconsultants.com According to a recently completed clinical trial, a vaccine that is injected directly into the site(s) of cancer produces promising results in patients with head and neck cancer who have stopped responding to standard therapies. Approximately 40,000 people in the United States are diagnosed with head and neck cancer every year. Cancers of the head and neck comprise several types of cancer, including the nasal cavity and sinuses, oral cavity, nasopharynx, oropharynx, and other sites located in the head and neck area. Once the cancer stops responding to standard therapeutic approaches, which typically consists of chemotherapy and/or radiation therapy, it is referred to as “refractory”. Patients with refractory head and neck cancer currently have very limited effective treatment options, with overall survival being dismal in this group of patients. There are currently no treatment modalities that have demonstrated an improvement in survival in the treatment of refractory head and neck cancer. Several clinical trials are underway to evaluate novel therapeutic approaches for the treatment of this disease. A novel vaccine Proxinium™ recently completed an early-phase clinical trial in the evaluation of advanced head and neck cancer. Proxinium™ is comprised of a monoclonal antibody, which is a protein that is targeted against and binds to a specific component of a cell. The monoclonal antibody portion of Proxinium™ is targeted against EpCAM, a molecule that is often highly expressed in head and neck cancer cells. Proxinium™ also contains the toxin produced by the bacterium Pseudomonas. When the [...]